Actithera has raised $75.5M in an oversubscribed Series A financing round, co-led by M Ventures, Hadean Ventures, and others, to advance its precision radioligand therapy.

Jul 09, 2025•about 1 month ago

Amount Raised

$75.5 Million

Round Type

series a

OsloBiotechnology

Investors

Arkin Bio Ventures IiSurveyor CapitalInvestinorInnovestor's Life Science FundBioqube Ventures4 Bio CapitalSofinnova PartnersHadean VenturesM Ventures

Description

Actithera, a biotech company focused on radioligand therapies, announced the completion of a $75.5 million Series A financing round. The funding will support the development of its lead FAP asset and proprietary radioligand discovery platform. The round was co-led by M Ventures and new investors including Hadean Ventures and Sofinnova Partners. Additional participation came from several venture firms, enhancing Actithera's capabilities in precision medicine.

Company Information

Company

Actithera

Location

Oslo, Oslo, Norway

About

Actithera is a radiopharmaceutical biotech company translating medicinal chemistry insights into next-generation radioligand therapies (RLTs). Founded in 2021 by drug discovery innovator Dr. Andreas Goutopoulos, and seed investors M Ventures, and Arkin Bio Ventures II, Actithera applies various molecular design strategies, including covalent-targeting and an isotope-agnostic philosophy to invent RLTs with significant differentiation and larger therapeutic windows. Headquartered in Oslo, Norway, and Cambridge, Massachusetts, Actithera is committed to advancing a differentiated pipeline addressing critical unmet needs in oncology.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends